27312152|t|Association of Low Ficolin - Lectin Pathway Parameters with Cardiac Syndrome X
27312152|a|In patients with typical angina pectoris, inducible myocardial ischaemia and macroscopically normal coronaries (cardiac syndrome X (CSX)), a significantly elevated plasma level of terminal complement complex (TCC), the common end product of complement activation, has been observed without accompanying activation of the classical or the alternative pathways. Therefore, our aim was to clarify the role of the ficolin - lectin pathway in CSX. Eighteen patients with CSX, 37 stable angina patients with significant coronary stenosis (CHD) and 54 healthy volunteers (HC) were enrolled. Serum levels of ficolin-2 and ficolin-3, ficolin-3 / MASP-2 complex and ficolin-3 -mediated TCC deposition (FCN3 - TCC) were determined. Plasma level of TCC was significantly higher in the CSX than in the HC or CHD group (5.45 versus 1.30 versus 2.04 AU/ml, P < 0.001). Serum levels of ficolin-2 and ficolin-3 were significantly lower in the CSX compared to the HC or CHD group (3.60 versus 5.80 or 5.20 μg/ml, P < 0.05; 17.80 versus 24.10 or 26.80 μg/ml, P < 0.05). The ficolin-3 / MASP-2 complex was significantly lower in the CSX group compared to the HC group (92.90 versus 144.90 AU/ml, P = 0.006). FCN3 - TCC deposition was significantly lower in the CSX group compared to the HC and CHD groups (67.8% versus 143.3% or 159.7%, P < 0.05). In the CSX group, a significant correlation was found between TCC and FCN3 - TCC level (r = 0.507, P = 0.032) and between ficolin-3 / MASP-2 complex level and FCN3 - TCC deposition (r = 0.651, P = 0.003). In conclusion, in patients with typical angina and myocardial ischaemia despite macroscopically normal coronary arteries, low levels of several lectin pathway parameters were observed, indicating complement activation and consumption. Complement activation through the ficolin - lectin pathway might play a role in the complex pathomechanism of CSX.
27312152	0	11	Association	T080	C0439849
27312152	19	26	Ficolin	T116,T123	C0217532
27312152	29	35	Lectin	T116,T123	C0023206
27312152	36	43	Pathway	T044	C0312755
27312152	44	54	Parameters	T077	C0549193
27312152	60	78	Cardiac Syndrome X	T047	C0206064
27312152	82	90	patients	T101	C0030705
27312152	96	119	typical angina pectoris	T184	C0002962
27312152	121	130	inducible	T169	C0205263
27312152	131	151	myocardial ischaemia	T047	C0151744
27312152	156	171	macroscopically	T080	C0439806
27312152	172	178	normal	T080	C0205307
27312152	179	189	coronaries	T023	C0018787
27312152	191	209	cardiac syndrome X	T047	C0206064
27312152	211	214	CSX	T047	C0206064
27312152	234	242	elevated	T080	C3163633
27312152	243	249	plasma	T031	C0032105
27312152	250	255	level	T080	C0441889
27312152	259	286	terminal complement complex	T116,T129	C0009545
27312152	288	291	TCC	T116,T129	C0009545
27312152	320	341	complement activation	T044	C0009528
27312152	352	360	observed	T169	C1441672
27312152	382	392	activation	T052	C1879547
27312152	400	409	classical	T044	C0009547
27312152	417	437	alternative pathways	T044	C0009546
27312152	454	457	aim	T078	C1947946
27312152	465	472	clarify	T052	C2986669
27312152	477	481	role	T077	C1705810
27312152	489	496	ficolin	T116,T123	C0217532
27312152	499	505	lectin	T116,T123	C0023206
27312152	506	513	pathway	T044	C0312755
27312152	517	520	CSX	T047	C0206064
27312152	531	539	patients	T101	C0030705
27312152	545	548	CSX	T047	C0206064
27312152	553	559	stable	T080	C0205360
27312152	560	566	angina	T184	C0002962
27312152	567	575	patients	T101	C0030705
27312152	581	592	significant	T078	C0750502
27312152	593	610	coronary stenosis	T047	C0242231
27312152	612	615	CHD	T047	C0242231
27312152	624	642	healthy volunteers	T098	C1708335
27312152	644	646	HC	T098	C1708335
27312152	653	661	enrolled	T062	C4041024
27312152	663	668	Serum	T031	C0229671
27312152	669	675	levels	T080	C0441889
27312152	679	688	ficolin-2	T116,T123	C0753749
27312152	693	702	ficolin-3	T116,T129	C1431109
27312152	704	713	ficolin-3	T116,T129	C1431109
27312152	716	722	MASP-2	T116,T123	C0537643
27312152	723	730	complex	T116,T123	C1180347
27312152	735	744	ficolin-3	T116,T129	C1431109
27312152	755	758	TCC	T116,T129	C0009545
27312152	759	769	deposition	T169	C0333562
27312152	771	775	FCN3	T116,T129	C1431109
27312152	778	781	TCC	T116,T129	C0009545
27312152	800	806	Plasma	T031	C0032105
27312152	807	812	level	T080	C0441889
27312152	816	819	TCC	T116,T129	C0009545
27312152	838	844	higher	T080	C0205250
27312152	852	855	CSX	T078	C0441833
27312152	868	870	HC	T098	C1708335
27312152	874	883	CHD group	T078	C0441833
27312152	933	938	Serum	T031	C0229671
27312152	939	945	levels	T080	C0441889
27312152	949	958	ficolin-2	T116,T123	C0753749
27312152	963	972	ficolin-3	T116,T129	C1431109
27312152	992	997	lower	T081	C1611820
27312152	1005	1008	CSX	T078	C0441833
27312152	1025	1027	HC	T098	C1708335
27312152	1031	1040	CHD group	T078	C0441833
27312152	1134	1143	ficolin-3	T116,T129	C1431109
27312152	1146	1152	MASP-2	T116,T123	C0537643
27312152	1153	1160	complex	T116,T123	C1180347
27312152	1179	1184	lower	T081	C1611820
27312152	1192	1195	CSX	T047	C0206064
27312152	1196	1201	group	T078	C0441833
27312152	1218	1226	HC group	T098	C1708335
27312152	1267	1271	FCN3	T116,T129	C1431109
27312152	1274	1277	TCC	T116,T129	C0009545
27312152	1278	1288	deposition	T169	C0333562
27312152	1307	1312	lower	T081	C1611820
27312152	1320	1323	CSX	T047	C0206064
27312152	1324	1329	group	T078	C0441833
27312152	1346	1348	HC	T098	C1708335
27312152	1353	1363	CHD groups	T078	C0441833
27312152	1414	1417	CSX	T047	C0206064
27312152	1418	1423	group	T078	C0441833
27312152	1439	1450	correlation	T080	C1707520
27312152	1469	1472	TCC	T116,T129	C0009545
27312152	1477	1481	FCN3	T116,T129	C1431109
27312152	1484	1487	TCC	T116,T129	C0009545
27312152	1488	1493	level	T080	C0441889
27312152	1529	1538	ficolin-3	T116,T129	C1431109
27312152	1541	1547	MASP-2	T116,T123	C0537643
27312152	1548	1555	complex	T116,T123	C1180347
27312152	1556	1561	level	T080	C0441889
27312152	1566	1570	FCN3	T116,T129	C1431109
27312152	1573	1576	TCC	T116,T129	C0009545
27312152	1577	1587	deposition	T169	C0333562
27312152	1630	1638	patients	T101	C0030705
27312152	1644	1658	typical angina	T184	C1998435
27312152	1663	1683	myocardial ischaemia	T047	C0151744
27312152	1692	1707	macroscopically	T080	C0439806
27312152	1708	1732	normal coronary arteries	T033	C1299335
27312152	1734	1737	low	T081	C1611820
27312152	1738	1744	levels	T080	C0441889
27312152	1756	1762	lectin	T116,T123	C0023206
27312152	1763	1770	pathway	T044	C0312755
27312152	1771	1781	parameters	T077	C0549193
27312152	1808	1829	complement activation	T044	C0009528
27312152	1834	1845	consumption	T039	C1947907
27312152	1847	1868	Complement activation	T044	C0009528
27312152	1881	1888	ficolin	T116,T123	C0217532
27312152	1891	1897	lectin	T116,T123	C0023206
27312152	1898	1905	pathway	T044	C0312755
27312152	1919	1923	role	T077	C1705810
27312152	1931	1938	complex	T080	C0439855
27312152	1939	1953	pathomechanism	T169	C0441712
27312152	1957	1960	CSX	T047	C0206064